Scientific Programme
In this edition of the ISMA-RHINA joint meeting, attendees will have a unique opportunity to participate in a prestigious gathering and access lectures presenting the most current knowledge and best practices in molecular allergology, rhinallergy, and related fields. This joint focused meeting aims to foster scientific collaboration and facilitate the translation of emerging discoveries into clinical applications for the benefit of our patients.
Our scientific program promises a comprehensive range of expertise:
- ISMA sessions will focus on the latest developments in molecular allergology and their impact on allergy diagnosis and therapy.
- RHINA sessions will explore cutting-edge science in allergy and immunology of the upper airways through a translational “bench to bedside” approach.
By attending the ISMA-RHINA joint meeting, the participants will:
- Learn from leaders and pioneers shaping the field’s future and network with them.
- Present your research to an international audience and receive valuable feedback and insights.
- Gain access to the latest research, trends, and developments in the field.
Highlights of the sessions
on Thursday 5 September
- Approaching CRSwNP and asthma with biologicals – RWE data Stefano Del Giacco (Italy)
- ESS and CRSwNP: to whom, when, how? Juan Maza Solano (Spain)
- Career development in rhinology: meet the expert Stella E. Lee (United States of America)
On Friday 6 September
- Novel treatment approaches in AR: AIT, Biolgicis or the combination? Ludger Klimek (Germany)
ISMA-RHINA 2024 brings together a diverse assembly of clinicians and scientists, ranging from junior researchers to key opinion leaders. Here are some teaser quotes from some of our top speakers to give you a glimpse of what they will be presenting:
Sanna Toppila-Salmi (Finland): Endotyping chronic rhinosinusitis patients.
“This symposium is vital for personalised treatment, allowing for targeted therapies based on specific inflammatory pathways. It aids in accurate diagnosis and predicts treatment response, ensuring more effective management. This approach also helps reduce chronicity and recurrence, improving long-term outcomes.”
Heimo Breiteneder (Austria): Unexpected features of allergens.
“The evolutionary biology of the Bet v 1 architecture began very early during the development of life, giving rise to the Bet v 1 superfamily of proteins whose members number in the tens of thousands and are present in archaea, bacteria and eukaryotes. Bet v 1 homologues fulfill a great variety of biological roles and are involved in different biosynthetic pathways. Without Bet v 1 homologues birch pollen would not be yellow, strawberries would not be red, and we would not be able to brew beer or produce certain kinds of painkillers.”
Barbara Bohle (Austria): Active immunotherapy with recombinant Bet v 1.
“Birch pollen allergy is very common in Central and Northern Europe and the major birch pollen allergen is one of the best characterized allergens. Besides its importance as marker allergen for the diagnosis of tree pollen allergy, recombinant Bet v 1 has been tested for its use for allergen immunotherapy. The respective results will be summarized and serve as basis to discuss tailor-made vaccines for the cure of allergy.”
Oliver Pfaar (Germany): AIT Explained!
“We will delve into the practical aspects of planning and executing allergen immunotherapy (AIT) in accordance with the latest state-of-the-art recommendations. Focusing on biologics and AIT, we will go through key topics, including evidence-based medicine and international guidelines, providing invaluable insights for clinicians and researchers alike”